Background Many patients with asthma have uncontrolled disease despite treatment with
inhaled glucocorticoids. One potential cause of the variability in response to treatment is …

Rationale: Chronic obstructive pulmonary disease (COPD) is a progressive, smoking-
related, inflammatory lung disease in which tumor necrosis factor-α is overexpressed and …

Background In phase 2 trials, lebrikizumab, an anti-interleukin-13 monoclonal antibody,
reduced exacerbation rates and improved FEV 1 in patients with uncontrolled asthma …

Anti-interleukin 4 and 13 for asthma treatment in the era of... : Current Opinion in Allergy and
Clinical Immunology Anti-interleukin 4 and 13 for asthma treatment in the era of endotypes …

Introduction In a subset of patients with asthma, standard-of-care treatment does not achieve
disease control, highlighting the need for novel therapeutic approaches. Lebrikizumab is a …

Background Asthma is a disease with marked heterogeneity in its clinical course and
response to treatment. IL-13 is central to type 2 inflammation, which contributes to many key …

A Retrospective Study of Epinephrine Administration for Anaphylaxis: How Many Doses Are
Needed? Page 1 Delivered by Ingenta to: Washington University School of Medicine Library …

A novel method of large-scale chromatography has been developed to improve recovery
and purity of immunoglobulin G (IgG) from pooled plasma. The current study compares …

Context: Acute asthma causes nearly 2 million hospital emergency department (ED) visits in
the United States annually, and hospitalization after an ED visit and relapse after ED …

Investigations were carried out to examine the possible causes of the low incidence and low
levels of anti-BSA in human adults as compared to those of normal children. To determine if …